# CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML

> **NCT04620681** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 19 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Secondary Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT04620681
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-14
- **Primary completion:** 2024-07-20
- **Final completion:** 2024-07-20
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620681, "CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04620681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*